UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

FORM 4

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden

Ľ		
	hours per response:	0.5
	Estimated average burden	

1. Name and Addre	1 0		2. Issuer Name and Ticker or Trading Symbol GALECTIN THERAPEUTICS INC [GALT]		ationship of Reporting Person(s) to Issuer < all applicable) Director 10% Owner		
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year)		Officer (give title below)	Other (specify below)	
C/O GALECTIN THERAPEUTICS INC.			03/12/2015				
4960 PEACHTREE INDUSTRIAL BLVD., STE 240				<u> </u>			
			4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv Line)	vidual or Joint/Group Filir	ng (Check Applicable	
(Street)				X	Form filed by One Re	oorting Person	
NORCROSS	GA	30071			Form filed by More that	0	
					Person		
(City)	(State)	(Zip)					

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	Date	2A. Deemed Execution Date, if any (Month/Day/Year)	Transaction Code (Instr.		4. Securities / Disposed Of (5)			5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(1130.4)
Common Stock	03/12/2015		A		1,784	A	\$ <mark>0</mark>	11,284	D	
Common Stock	04/08/2015		Α		25,483	A	\$ <mark>0</mark>	36,767	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (right to buy)	\$8.1	04/08/2015		D			14,815	(1)	06/02/2021	Common Stock	14,815	(2)	0	D	
Stock Option (right to buy)	\$3.59	04/08/2015		D			16,714	(3)	03/28/2023	Common Stock	16,714	(2)	0	D	

Explanation of Responses:

1. The option vested quarterly in eight equal installments beginning September 2, 2011.

2. The option was canceled by mutual agreement of the reporting person and Galectin Therapeutics, Inc. The reporting person received 25,483 shares of restricted common stock, reported in Table 1 of this Form 4, as consideration for the cancellation of options granted on June 2, 2011 and March 28, 2013.

3. The option vested quarterly in eight equal installments beginning on May 12, 2013.

Remarks:

<u>/s/ Jack W. Callicutt as Power</u> of Attorney for Herman Paul

Pressler

07/08/2015

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.